Skip to content
Companies

Cambrian BioPharma

Drugs that target the biology of aging

Raised to date

$123.8M

of $129.8M offered across 1 Form D filing

Still open
$6M
Investors
80
Last filed
Jul 15, 2026

About

Cambrian Bio (Cambrian BioPharma, Inc.) is a New York-based clinical-stage drug development company building therapeutics that target the biological drivers of aging to extend healthspan. It operates as a Distributed Development Company (DisCo), advancing more than a dozen programs through pipeline companies such as Amplifier Therapeutics and Tornado Therapeutics. Its lead asset, ATX-304, is described as the first AMPK Network Activator to enter clinical development and has reported positive Phase 1b results in obesity and prediabetes. Founded in 2019 by CEO James Peyer, the company has raised over $200 million.

A distributed pipeline-company model that advances multiple clinical programs in parallel, each targeting a distinct biological driver of aging, rather than betting the company on a single asset.

Funding

  • EquityFiled Jul 15, 2026Form D
    $123.8M/ $129.8M

Product

ATX-304

Clinical-stage therapeutic

A pan-AMPK activator in clinical development (via pipeline company Amplifier Therapeutics) targeting age-related metabolic decline, with positive Phase 1b results in obesity and prediabetes.

  • First AMPK Network Activator to enter clinical development
  • Positive Phase 1b results in obesity and prediabetes
  • Targets metabolic pathways including AMPK and mTOR

Built for

Patients with aging-related metabolic diseases such as obesity and prediabetes, reached through eventual pharmaceutical partnerships and commercialization

People on file